Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Popped Today

By Joe Tenebruso - Updated Jun 7, 2021 at 5:48PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech is ramping up its global coronavirus vaccination efforts.

What happened

Shares of Moderna (MRNA -2.81%) jumped 6.2% on Wednesday after the drugmaker announced that it had requested permission to administer its COVID-19 vaccine candidate to adolescents in Canada and the European Union. 

So what

Moderna said in May that a phase 2/3 clinical trial of its vaccine in adolescents demonstrated 93% efficacy against mild COVID-19 and 100% against a more severe classification of the disease among the study's nearly 2,500 participants who received its drug. The vaccine was also generally well tolerated, with no significant safety concerns identified during the trial. 

A syringe is placed in a drug vial next to other vials.

Moderna is seeking the ability to distribute its coronavirus vaccine for adolescents. Image source: Getty Images.

Moderna believes these promising results could allow it to obtain authorization of its vaccine in adolescents from Health Canada and a conditional marketing approval (CMA) from the European Medicines Agency (EMA). The biotech also said it intends to file for an Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) and other international regulatory agencies.  

Now what 

In anticipation of these potential regulatory authorizations, Moderna struck a deal with Medison Pharma to distribute its COVID-19 vaccine in Israel and 20 European countries. The agreement could help to bring Moderna's lifesaving drug to as many as 175 million people in these markets. 

"Working together with our partners, we remain steadfast in our commitment to fighting the pandemic by delivering our vaccine to populations globally," Moderna Chief Commercial Officer Corinne Le Goff said in a press release. 

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$177.79 (-2.81%) $-5.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
379%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.